Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37


Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center.

Laird CM, Glode AE, Schwarz K, Lam ET, O'Bryant CL.

J Oncol Pharm Pract. 2020 Jan 19:1078155219895312. doi: 10.1177/1078155219895312. [Epub ahead of print] No abstract available.


A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.

Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP.

Br J Clin Pharmacol. 2019 Nov;85(11):2499-2511. doi: 10.1111/bcp.14054. Epub 2019 Sep 4.


Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.

Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant CL, Bowles DW, George B, Wen X, Buckley B, Aleksunes L, Joy MS.

Eur J Clin Pharmacol. 2019 Jan;75(1):51-57. doi: 10.1007/s00228-018-2552-z. Epub 2018 Sep 15.


Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer.

El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T, El-Rayes BF.

Cancer Chemother Pharmacol. 2018 Apr;81(4):659-670. doi: 10.1007/s00280-018-3517-8. Epub 2018 Feb 21.


Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.

Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D.

Mol Cancer Ther. 2018 Jan;17(1):215-221. doi: 10.1158/1535-7163.MCT-17-0330. Epub 2017 Oct 20.


Implementation of a pharmacist-managed clinic for patients with chronic nonmalignant pain.

Norman JL, Kroehl ME, Lam HM, Lewis CL, Mitchell CN, O'Bryant CL, Trinkley KE.

Am J Health Syst Pharm. 2017 Aug 15;74(16):1229-1235. doi: 10.2146/ajhp160294.


Silibinin Treatment Inhibits the Growth of Hedgehog Inhibitor-Resistant Basal Cell Carcinoma Cells via Targeting EGFR-MAPK-Akt and Hedgehog Signaling.

Dheeraj A, Rigby CM, O'Bryant CL, Agarwal C, Singh RP, Deep G, Agarwal R.

Photochem Photobiol. 2017 Jul;93(4):999-1007. doi: 10.1111/php.12727. Epub 2017 Mar 6.


Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.

Page RL 2nd, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research.

Circulation. 2016 Aug 9;134(6):e32-69. doi: 10.1161/CIR.0000000000000426. Epub 2016 Jul 11. Review. Erratum in: Circulation. 2016 Sep 20;134(12):e261.


Board-Certified Oncology Pharmacists: Their Potential Contribution to Reducing a Shortfall in Oncology Patient Visits.

Ignoffo R, Knapp K, Barnett M, Barbour SY, D'Amato S, Iacovelli L, Knudsen J, Koontz SE, Mancini R, McBride A, McCauley D, Medina P, O'Bryant CL, Scarpace S, Stricker S, Trovato JA.

J Oncol Pract. 2016 Apr;12(4):e359-68. doi: 10.1200/JOP.2015.008490. Epub 2016 Mar 22.


Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.

Jerjian TV, Glode AE, Thompson LA, O'Bryant CL.

Pharmacotherapy. 2016 Jan;36(1):99-116. doi: 10.1002/phar.1687. Review.


The need for PGY2-trained clinical pharmacy specialists.

Ragucci KR, O'Bryant CL, Campbell KB, Buck ML, Dager WE, Donovan JL, Emerson K, Gubbins PO, Haight RJ, Jackevicius C, Murphy JE, Prohaska E.

Pharmacotherapy. 2014 Jun;34(6):e65-73. doi: 10.1002/phar.1430. Epub 2014 Apr 18.


Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors.

Thompson LA, Saseen JJ, O'Bryant CL, Allen RR, Nair KV.

J Oncol Pharm Pract. 2015 Aug;21(4):258-67. doi: 10.1177/1078155214530177. Epub 2014 Apr 11.


Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL.

Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. Review.


Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

O'Bryant CL, Wenger SD, Kim M, Thompson LA.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Review.


Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.

Kim M, Thompson LA, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Oct;46(10):1340-8. doi: 10.1345/aph.1R036. Epub 2012 Sep 11. Review.


Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4. Review.


A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.

Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A.

Clin Cancer Res. 2012 Aug 1;18(15):4173-82. doi: 10.1158/1078-0432.CCR-12-0714. Epub 2012 Jun 12.


The intersection between cannabis and cancer in the United States.

Bowles DW, O'Bryant CL, Camidge DR, Jimeno A.

Crit Rev Oncol Hematol. 2012 Jul;83(1):1-10. doi: 10.1016/j.critrevonc.2011.09.008. Epub 2011 Oct 21. Review.


An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.

O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S.

Cancer Chemother Pharmacol. 2012 Mar;69(3):605-12. doi: 10.1007/s00280-011-1733-6. Epub 2011 Sep 22.


A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.

Lam ET, O'Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden SN, Dancey J, Eckhardt SG, Gore L.

Mol Cancer Ther. 2008 Dec;7(12):3685-94. doi: 10.1158/1535-7163.MCT-08-0436.


Community pharmacists' knowledge of and attitudes toward oral chemotherapy.

O'Bryant CL, Crandell BC.

J Am Pharm Assoc (2003). 2008 Sep-Oct;48(5):632-9. doi: 10.1331/JAPhA.2008.07082.


Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.

Gibson K, O'Bryant CL.

J Oncol Pharm Pract. 2008 Sep;14(3):139-45. doi: 10.1177/1078155208091866.


Bicalutamide-associated fulminant hepatotoxicity.

O'Bryant CL, Flaig TW, Utz KJ.

Pharmacotherapy. 2008 Aug;28(8):1071-5. doi: 10.1592/phco.28.8.1071.


A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.

Lieu C, Chow L, Pierson AS, Eckhardt SG, O'Bryant CL, Morrow M, Tran ZV, Wright JJ, Gore L.

Invest New Drugs. 2009 Feb;27(1):53-62. doi: 10.1007/s10637-008-9154-z. Epub 2008 Jul 11.


A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.

Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, Coffin D, McCoy C, Schott A, Scholz C, Eckhardt SG.

Clin Cancer Res. 2008 Jul 15;14(14):4517-25. doi: 10.1158/1078-0432.CCR-07-1461. Epub 2008 Jun 25.


A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.

O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG.

Cancer Chemother Pharmacol. 2009 Feb;63(3):477-89. doi: 10.1007/s00280-008-0761-3. Epub 2008 May 29.


A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.

Chow LQ, Gustafson DL, O'Bryant CL, Gore L, Basche M, Holden SN, Morrow MC, Grolnic S, Creese BR, Roberts KL, Davis K, Addison R, Eckhardt SG.

Cancer Chemother Pharmacol. 2008 Dec;63(1):65-74. doi: 10.1007/s00280-008-0712-z. Epub 2008 Mar 5.


Inconsistencies in opioid equianalgesic ratios: clinical and research implications.

O'Bryant CL, Linnebur SA, Yamashita TE, Kutner JS.

J Pain Palliat Care Pharmacother. 2008;22(4):282-90. doi: 10.1080/15360280802537241.


A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.

Chow LQ, Eckhardt SG, O'Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L.

Cancer Chemother Pharmacol. 2008 Sep;62(4):631-46. Epub 2007 Dec 6.


A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.

Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD.

Anticancer Drugs. 2008 Jan;19(1):77-84.


Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.

Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG.

Ann Oncol. 2007 Aug;18(8):1400-7.


A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.

Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ.

Clin Cancer Res. 2007 Apr 1;13(7):2091-9.


A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.

Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG.

Clin Cancer Res. 2006 Sep 15;12(18):5471-80.


A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.

Gore L, Holden SN, Cohen RB, Morrow M, Pierson AS, O'Bryant CL, Persky M, Gustafson D, Mikule C, Zhang S, Palmer PA, Eckhardt SG.

Ann Oncol. 2006 Nov;17(11):1709-17. Epub 2006 Sep 15.


Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.

Kobayashi H, Eckhardt SG, Lockridge JA, Rothenberg ML, Sandler AB, O'Bryant CL, Cooper W, Holden SN, Aitchison RD, Usman N, Wolin M, Basche ML.

Cancer Chemother Pharmacol. 2005 Oct;56(4):329-36. Epub 2005 May 20.


A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.

Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA Jr, Chan DC, Pallansch P, Eckhardt SG.

Clin Cancer Res. 2004 Nov 1;10(21):7229-37.


Antiinflammatory and analgesic activity of an inhibitor of neuropeptide amidation.

Ogonowski AA, May SW, Moore AB, Barrett LT, O'Bryant CL, Pollock SH.

J Pharmacol Exp Ther. 1997 Feb;280(2):846-53.


Supplemental Content

Loading ...
Support Center